leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical's stock split to take place on May 24

Shareholders have previously agreed the move, which will be on the basis of five new shares for each one existing (5:1)..

price screen
The split will take place tomorrow (Thursday)
Health sciences and preventative medicines firm PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) says its previously announced stock split will take place on May 24 this year.
 
Shareholders have previously agreed the move, which will be on the basis of five new shares for each one existing (5:1).
 
As of today (Wednesday), shares have begun trading on the Canadian Securities Exchange on an ex-distribution basis.
 
Preveceutical develops innovative options for preventive and curative therapies utilising organic and nature identical products.
 
"We believe the stock split demonstrates the company's continued commitment to broaden its shareholder base and we anticipate that the stock split will make PreveCeutical's securities more accessible to investors and enhance liquidity for shareholders,” president and chairman Stephen Van Deventer said earlier this month.

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

CSE:PREV
Market: CSE
Market Cap: $17.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read